/HLN
HLN Stock - Haleon plc
Healthcare|Drug Manufacturers - Specialty & GenericNYSE
$9.90+0.61%
+$0.06 (+0.61%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.57
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).56
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+3.0%upside
Target: $10.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HLN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.80 – $10.00
TARGET (TP)$10.20
STOP LOSS$9.11
RISK/REWARD1:0.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.23
52W High$11.42
52W Low$8.71
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $11.23B | $11.30B | $10.86B | $9.54B | $9.89B |
| Gross Profit | $6.95B | $6.96B | $6.58B | $5.95B | $5.91B |
| Gross Margin | 61.9% | 61.6% | 60.6% | 62.3% | 59.7% |
| Operating Income | $2.21B | $2.00B | $1.82B | $1.64B | $1.60B |
| Net Income | $1.44B | $1.05B | $1.06B | $1.39B | $1.15B |
| Net Margin | 12.8% | 9.3% | 9.8% | 14.6% | 11.6% |
| EPS | $0.32 | $0.24 | $0.24 | $0.30 | $0.24 |
Company Overview
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
57%
Hold / Neutral
6
43%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
8 Bullish6 Neutral/Bearish
Price Targets
$11
Average Target
↑ 10.2% Upside
Now
$9
Low
$11
Average
$13
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 16th 2025 | Barclays | Downgrade | Equal Weight | - |
| September 10th 2025 | Goldman | Upgrade | Buy | - |
| May 27th 2025 | BNP Paribas Exane | Upgrade | Outperform | $13.4 |
| May 9th 2025 | Morgan Stanley | Upgrade | Overweight | $11.25 |
| March 5th 2025 | HSBC Securities | Downgrade | Hold | - |
| January 10th 2025 | Morgan Stanley | Downgrade | Equal Weight | - |
| January 8th 2025 | Bernstein | Downgrade | Market Perform | - |
| August 6th 2024 | Berenberg | Initiation | Buy | - |
| August 6th 2024 | Goldman | Downgrade | Neutral | - |
| June 5th 2024 | Berenberg | Initiation | Buy | - |
| April 17th 2024 | HSBC Securities | Initiation | Buy | - |
| December 11th 2023 | Jefferies | Resumed | Buy | - |
| November 1st 2023 | Morgan Stanley | Initiation | Overweight | $9 |
| May 24th 2023 | Stifel | Initiation | Hold | - |
| April 6th 2023 | Argus | Upgrade | Buy | $10 |
Earnings History & Surprises
HLNBeat Rate
22%
Last 9 quarters
Avg Surprise
-31.6%
EPS vs Estimate
Beats / Misses
2/7
Last 12 quarters
Latest EPS
$0.14
Q4 2025
EPS Surprise History
Q1 23
-9.7%
$0.21vs$0.23
Q3 23
-63.5%
$0.08vs$0.22
Q1 24
-36.3%
$6.54vs$10.27
Q2 24
+9.1%
$0.12vs$0.11
Q4 24
+27.3%
$0.14vs$0.11
Q1 25
-99.8%
$0.05vs$25.25
Q3 25
-67.3%
$0.08vs$0.24
Q4 25
-42.8%
$0.14vs$0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.24 | $0.14 | -42.8% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $0.24 | $0.08 | -67.3% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $25.25 | $0.05 | -99.8% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $0.11 | $0.14 | +27.3% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $0.11 | $0.12 | +9.1% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $10.27 | $6.54 | -36.3% | ✗ MISS |
Q3 2023 | Aug 2, 2023 | $0.22 | $0.08 | -63.5% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $0.23 | $0.21 | -9.7% | ✗ MISS |
Q3 2022 | Sep 20, 2022 | $0.22 | $0.22 | -1.6% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $0.11 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.07 | — | — |
Latest News
Altibbi Teams Up With Sensodyne Maker To Boost Oral Health Access In Saudi Arabia
📈 PositiveBenzinga•Nov 24, 2025, 11:20 AM
Haleon Partners With Salesforce To Enhance Global Engagement With Pharmacies Using AI-Powered Solutions
📈 PositiveBenzinga•Oct 8, 2025, 02:26 PM•Also: ,
Haleon downgraded at Barclays on US consumer slowdown; falls on LSE
📉 NegativeSeeking Alpha•Sep 16, 2025, 02:52 PM•Also: ,
Haleon shares are trading lower after Barclays downgraded the stock from Overweight to Equal-Weight.
📉 NegativeBenzinga•Sep 16, 2025, 11:58 AM•Also: ,
Barclays Downgrades Haleon to Equal-Weight
📉 NegativeBenzinga•Sep 16, 2025, 10:50 AM•Also: ,
HHS Spokesperson Tells CNBC On Forthcoming Autism Report, 'Until We Release Final Report, Claims About Its Contents Are Nothing More Than Speculation'
➖ NeutralBenzinga•Sep 5, 2025, 07:29 PM•Also: , ,
Frequently Asked Questions about HLN
What is HLN's current stock price?
Haleon plc (HLN) is currently trading at $9.90 per share. The stock has moved +0.61% today.
What is the analyst price target for HLN?
The average analyst price target for HLN is $10.20, based on 1 analyst.
What sector is Haleon plc in?
Haleon plc operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.
What is HLN's market cap?
Haleon plc has a market capitalization of $44.86 billion, making it a large-cap company.
Does HLN pay dividends?
No, Haleon plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorA
Agilent Technologies, Inc.
$137.24
Mkt Cap: $38.9B
ALC
Alcon Inc.
$79.97
Mkt Cap: $39.6B
BDX
Becton, Dickinson and Company
$195.59
Mkt Cap: $56.3B
CAH
Cardinal Health, Inc.
$202.95
Mkt Cap: $48.2B
HUM
Humana Inc.
$259.40
Mkt Cap: $31.2B
INSM
Insmed Incorporated
$174.84
Mkt Cap: $37.3B
IQV
IQVIA Holdings Inc.
$220.66
Mkt Cap: $37.6B
RMD
ResMed Inc.
$244.94
Mkt Cap: $35.9B
TAK
Takeda Pharmaceutical Company Limited
$14.90
Mkt Cap: $47.0B
ZTS
Zoetis Inc.
$122.24
Mkt Cap: $53.9B
Explore stocks similar to HLN for comparison